Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Clearbridge Health Limited (1H3.SI)
Singapore, SG
Established in 2010 and headquartered in Singapore, Clearbridge Health Limited operates as an investment holding company, delivering diverse healthcare solutions globally, including in Singapore, the Philippines, Hong Kong, and Malaysia. The firm's activities are organized into three key divisions: Strategic Investments, Healthcare Systems, and Medical Clinics/Centres. Its extensive range of services encompasses advanced imaging diagnostics, such as general X-ray, CT scans (including dental cone beam), mammography, MRI, and ultrasound. Furthermore, Clearbridge offers general wellness screenings for conditions like diabetes, high blood pressure, and elevated cholesterol, alongside vaccination programs. Specialized care includes renal treatment, clinical services, aesthetic procedures, and dental and orthodontic services. Beyond patient care, the company provides consultancy to healthcare organizations and is involved in the wholesale supply of medicinal and pharmaceutical products.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -50.00% | +0.00% | +0.00% | -50.00% | -50.00% | -50.00% | -75.00% | -75.00% | -75.00% | -75.00% | -75.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Diagnostics & Research: +7.9%+0.3% Q4'25: +65.8% (vs Q4'23)
-
EPS growth Medical - Diagnostics & Research: +30.8%+25.0% Q4'25: -59.1% (vs Q4'23)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-128.2% Q4'25: -27.3% (vs Q4'23)
-
EBIT margin Medical - Diagnostics & Research: +9.6%-127.5% Q4'25: -221.4% (vs Q4'23)
-
ROIC Medical - Diagnostics & Research: +5.2%-221.7% Q4'25: -777.2% (vs Q4'23)
-
Share dilution Medical - Diagnostics & Research: 0.0%+378.7% Q4'25: +431.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×-0.13× Q4'25: -0.03× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
|---|---|---|
| Revenue |
10.41M
est: 62.13M (-83.3%)
|
9.90M
est: 65.24M (-84.8%)
|
| EBITDA |
-32.18M
est: -29.04M (-10.8%)
|
-2.06M
est: -43.60M (+95.3%)
|
| EBIT |
-33.53M
est: -38.29M (+12.4%)
|
-3.47M
est: -51.96M (+93.3%)
|
| Net Income |
-32.20M
|
-3.61M
|
| SGA |
—
est: 2.73M (-100.0%)
|
—
est: 191.9K (-100.0%)
|
| EPS |
-0.05
|
-0.01
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pinh Yee | Chief Executive Officer & Executive Director | 524.0K | male |
| Kia Wei Hoo | Chief Business Officer | — | male |
| Moi Heyang Lin | Joint Company Secretary | — | female |
| Pei Chan Tang | Joint Company Secretary | — | female |
| Wei Chee Tan | Financial Controller | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1H3.SI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
